ARCHIMED has successfully completed the acquisition of IBA Lifesciences GmbH by Cube Biotech, marking a significant milestone for Cube. This acquisition enhances Cube's protein purification portfolio, strengthens its market position, and is expected to improve profitability.

IBA Lifesciences, based in Germany, specializes in life science tools, particularly reagents for protein purification using its proprietary Strep-Tag® affinity technology. The company has been a long-time customer of Cube Biotech, utilizing its Magnetic Beads for protein purification, which are compatible with IBA’s technology.

This strategic move aligns with Cube Biotech’s goal to foster innovation, streamline services, and broaden its global reach. The acquisition follows several key partnerships established over the past year. By merging its expertise in protein technologies with IBA’s research tools, Cube aims to meet the evolving demands of researchers and industry professionals worldwide.

The combined entity will offer a comprehensive range of affinity-tag purification technologies, further driving innovation in biotechnology. This positions Cube as a leader in membrane protein production and purification technologies. Didier Dargent, CEO of Cube Biotech, expressed enthusiasm about the acquisition, stating it opens a new chapter for both companies and will enable groundbreaking discoveries in life sciences.

Dr. Mike Rothe, CEO of IBA Lifesciences, echoed this sentiment, highlighting that the merger of their technologies and talents will create a strong foundation for innovation, ultimately benefiting customers and enhancing their leadership in the biotechnology sector.

Cube Biotech, headquartered in Monheim, Germany, is recognized for its high-quality solutions in protein purification, stabilization, and structural studies. Since becoming part of ARCHIMED in 2021, Cube has continued to serve researchers in both academia and industry.

ARCHIMED is a prominent investment firm focused exclusively on healthcare industries, with offices in Europe, North America, and Asia. The firm combines operational, medical, scientific, and financial expertise to act as both a strategic and financial partner to healthcare businesses. ARCHIMED prioritizes investments in various sectors, including biopharma products, consumer health, healthcare IT, in vitro diagnostics, life science tools, MedTech, and pharma services.

With €8 billion managed across its funds, ARCHIMED is committed to impact investing, both directly and through its EURÊKA Foundation. The firm aims to assist partners in internationalizing, acquiring, innovating, and expanding their products and services.

In summary, the acquisition of IBA Lifesciences by Cube Biotech, facilitated by ARCHIMED, is set to enhance Cube's capabilities in protein purification and innovation in the biotechnology sector, benefiting researchers and the industry at large.